Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that is generally considered to be T cell-driven. Accordingly, most strategies of immunotherapy for T1D prevention and treatment in the clinic have targeted the T cell compartment. To date, however, immunotherapy has had only limited clinical success. A...
Main Authors: | Charles J. Kroger, Matthew Clark, Qi Ke, Roland M. Tisch |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01891/full |
Similar Items
-
Evolving Antibody Therapies for the Treatment of Type 1 Diabetes
by: Qi Ke, et al.
Published: (2021-02-01) -
The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes
by: Matthew Clark, et al.
Published: (2021-02-01) -
Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response
by: Matthew Clark, et al.
Published: (2017-12-01) -
Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases
by: Naomi Richardson, et al.
Published: (2020-07-01) -
Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation
by: Brett E. Phillips, et al.
Published: (2021-03-01)